Vandria SA
We develop first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases
We develop first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases
Vandria SA is a biopharmaceutical company based in Switzerland that specializes in developing first-in-class mitophagy inducers to combat age-related and chronic diseases in the fields of Muscle- and CNS diseases with large unmet medical need. Its slogan, "We develop first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases," encapsulates the company's mission and focus.
The company recently secured a Fr.3.50M Grant investment on 08 February 2024 from Innosuisse and Eurostars. This investment signifies a vote of confidence in Vandria's potential to make significant strides in treating diseases that have a high impact on individuals and society as a whole.
Vandria operates in the Manufacturing and Pharmaceutical industries and aims to leverage its expertise to provide innovative solutions to pressing healthcare challenges. With its focus on developing small molecule mitophagy inducers, Vandria is positioned at the forefront of cutting-edge medical research and holds promise for addressing unmet medical needs in the treatment of age-related and chronic diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | Fr.3.50M | 2 |
|
08 Feb 2024 |
| Series A | Fr.18.00M | 1 |
|
14 Dec 2023 |
No recent news or press coverage available for Vandria SA.
We care about your data, and we'd love to use cookies make your experience better.
